Suvretta Capital Management, LLC Otonomy, Inc. Transaction History

Suvretta Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.72 - $2.47 $801,659 - $1.15 Million	466,081 Added 17.4%	3,144,196 $7.55 Million
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.31 $490,801 - $670,858	290,415 Added 12.16%	2,678,115 $5.57 Million
Q3 2021 Nov 16, 2021	SELL	$1.22 - $2.2 $5.42 Million - $9.78 Million	-4,444,444 Reduced 65.05%	2,387,700 $4.58 Million
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $5.42 Million - $9.78 Million	4,444,444 Added 186.14%	6,832,144 $13.1 Million
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $674,650 - $874,425	327,500 Added 15.9%	2,387,700 $5.33 Million
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $3.58 Million - $8.96 Million	1,437,500 Added 230.85%	2,060,200 $5.25 Million
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $1.3 Million - $2.41 Million	372,700 Added 149.08%	622,700 $4.03 Million
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $790,000 - $1.09 Million	250,000 New	250,000 $1.01 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Suvretta Capital Management, LLC with notifications on news.